Artifactual laboratory abnormalities in patients with paraproteinemia

Southern Medical Journal

Volumn 102, Issue 2, 2009, Pages 167-170

  Roy, Vivek ^a  

^a MAYO CLINIC   (United States)

Author keywords

Laboratory abnormalities; Monoclonal gammopathy; Paraprotein; Spurious

Indexed keywords

ELECTROLYTE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARAPROTEIN; BIOLOGICAL MARKER;

ABNORMAL LABORATORY RESULT; ARTICLE; ARTIFACT; BLOOD CELL COUNT; CALCIUM BLOOD LEVEL; DIAGNOSTIC ERROR; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDICAL PRACTICE; MONOCLONAL IMMUNOGLOBULINEMIA; PARAPROTEINEMIA; PHOSPHATE BLOOD LEVEL; PREVALENCE; SODIUM BLOOD LEVEL; TREATMENT PLANNING; UNNECESSARY PROCEDURE; BLOOD; BLOOD ANALYSIS; CHEMISTRY; METHODOLOGY; REVIEW;

ARTIFACTS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; DIAGNOSTIC ERRORS; HUMANS; PARAPROTEINEMIAS; PARAPROTEINS;

EID: 63249084204     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181831f6a     Document Type: Article

References (39)

1. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354: 1362-1369.
2. Iwanaga M, Tagawa M, Tsukasaki K, et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007;82:1474 -1479.
3. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007;82:1468 -1473.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43- 66.
5. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998;82:1078 -1081.
6. Sheppard CA, Allen RC, Austin GE, et al. Paraprotein interference in automated chemistry analyzers. Clin Chem 2005;51:1077-1078.
7. Bowles SA, Tait RC, Jefferson SG, et al. Characteristics of monoclonal immunoglobulins that interfere with serum inorganic phosphate measurement. Ann Clin Biochem 1994;31(pt 3):249 -254.
8. Sonnenblick M, Eylath U, Brisk R, et al. Paraprotein interference with colorimetry of phosphate in serum of some patients with multiple myeloma. Clin Chem 1986;32:1537-1539.
9. Yamada K, Yagihashi A, Ishii S, et al. Interference with nephelometric assay of C-reactive protein and antistreptolysin-O by monoclonal IgMkappa from a myeloma patient. Clin Chem 1997;43:2435-2437.
10. Merlini G, Farhangi M, Osserman EF. Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. Semin Oncol 1986;13:350 -365.
11. Shoenfeld Y, el-Roeiy A, Ben-Yehuda O, et al. Detection of anti-histone activity in sera of patients with monoclonal gammopathies. Clin Immunol Immunopathol 1987;42:250 -258.
12. Waldenstrom JG. Antibody activity of monoclonal immunoglobulins in myeloma, macroglobulinemia and benign gammapathy. Med Oncol Tumor Pharmacother 1986;3:135-140.
13. Robert F, Mignucci M, McCurdy SA, et al. Hemostatic abnormalities associated with monoclonal gammopathies. Am J Med Sci 1993;306: 359-366.
14. Spicka I, Rihova Z, Kvasnicka J, et al. Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis. Thromb Res 2003;112: 297-300.
15. Haeney MR. Erroneous values for the total white cell count and ESR in patients with cryoglobulinaemia. J Clin Pathol 1976;29:894-897.
16. Roberts WL, Fontenot JD, Lehman CM. Overestimation of hemoglobin in a patient with an IgA-kappa monoclonal gammopathy. Arch Pathol Lab Med 2000;124:616-618.
17. Gumprecht T, O'Connor DT, Rearden A, et al. Negative anion gap in a young adult with multiple myeloma. Clin Chem 1976;22:1920 -1921.
18. Valdivieso A, Costa M, Robino X, et al. [Pseudohyponatremia and anion gap changes in multiple myeloma]. Rev Med Chil 1989;116:559 -562.
19. Vaswani SK, Sprague R. Pseudohyponatremia in multiple myeloma. South Med J 1993;86:251-252.
20. Sachs J, Fredman B. The hyponatramia of multiple myeloma is true and not pseudohyponatramia. Med Hypotheses 2006;67:839-840.
21. Adler SG, Laidlaw SA, Lubran MM, et al. Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 1988;11:260 -263.
22. Mandry JM, Posner MR, Tucci JR, et al. Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. Cancer 1991;68: 1092-1094.
23. Oren S, Feldman A, Turkot S, et al. Hyperphosphatemia in multiple myeloma. Ann Hematol 1994;69:41- 43.
24. Sinclair D, Smith H, Woodhead P. Spurious hyperphosphataemia caused by an IgA paraprotein: a topic revisited. Ann Clin Biochem 2004;41(pt 2):119 -124.
25. McClure D, Lai LC, Cornell C. Pseudohyperphosphataemia in patients with multiple myeloma. J Clin Pathol 1992;45:731-732.
26. Kiki I, Gundogdu M, Kaya H. Spuriously high phosphate level which is promptly resolved after plasmapheresis in a patient with multiple myeloma. Transfus Apher Sci 2007;37:157-159.
27. Pierce GF, Garrett NC, Koenig J, et al. Interference by monoclonal proteins in the o-phthalaldehyde method for blood urea nitrogen. Clin Chim Acta 1986;154:233-236.
28. Smith JD, Nobiletti J, Freed M, et al. Interference with the Astra 8 and Synchron CX3 assays of urea nitrogen in serum by a high-M(r) inhibitor in a patient with multiple myeloma. Clin Chem 1992;38:598 -599.
29. Datta P, Graham GA, Schoen I. Interference by IgG paraproteins in the Jaffe method for creatinine determination. Am J Clin Pathol 1986;85: 463-468.
30. Pantanowitz L, Horowitz GL, Upalakalin JN, et al. Artifactual hyperbilirubinemia due to paraprotein interference. Arch Pathol Lab Med 2003; 127:55-59.
31. Nauti A, Barassi A, Merlini G, et al. Paraprotein interference in an assay of conjugated bilirubin. Clin Chem 2005;51:1076 -1077.
32. John R, Oleesky D, Issa B, et al. Pseudohypercalcaemia in two patients with IgM paraproteinaemia. Ann Clin Biochem 1997;34(pt 6):694-696.
33. Bakker AJ. Influence of monoclonal immunoglobulins in direct determinations of iron in serum. Clin Chem 1991;37:690-694.
34. Hachem H, Favre G, Ghalim N, et al. Quantitative abnormalities of lipoprotein particles in multiple myeloma. J Clin Chem Clin Biochem 1987;25:675- 679.
35. Baca A, Haber RJ, Sujishi K, et al. Artifactual undetectable HDL-cholesterol with the Beckman synchron LX and vitros 950 assays temporally associated with a paraprotein. Clin Chem 2004;50:255-256.
36. Tsai LY, Tsai SM, Lee SC, et al. Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. Clin Chim Acta 2005; 358:192-195.
37. Kadri N, Douville P, Lachance P. Monoclonal paraprotein may interfere with the Roche direct HDL-C Plus assay. Clin Chem 2002;48(6 pt 1): 964.
38. Yang Y, Howanitz PJ, Howanitz JH, et al. Paraproteins are a common cause of interferences with automated chemistry methods. Arch Pathol Lab Med 2008;132:217-223.
39. Berth M, Delanghe J. Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. Acta Clin Belg 2004;59:263-273.